Stifel Nicolaus analyst Konstantinos Aprilakis reiterated a Buy rating on Syndax Pharmaceuticals (NASDAQ:SNDX) Inc on Tuesday, setting a price target of $39, which is approximately 65.39% above the present share price of $23.58.
Aprilakis expects Syndax Pharmaceuticals Inc to post earnings per share (EPS) of -$0.46 for the first quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Syndax Pharmaceuticals, with an average price target of $35.33.
The analysts price targets range from a high of $39 to a low of $30.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $379 thousand and a net profit of -$19.85 million. The company's market cap is $1.11 billion.
According to TipRanks.com, Stifel Nicolaus analyst Konstantinos Aprilakis is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -7.5% and a 29.69% success rate.
Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include candidate and entinostat. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.